InterMune, Inc.
(NASDAQ : ITMN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.08%132.190.0%$1230.60m
OCGNOcugen, Inc. -2.56%8.740.0%$941.39m
NVAXNovavax, Inc. 10.59%174.8492.9%$613.91m
REGNRegeneron Pharmaceuticals, Inc. 2.71%461.572.7%$556.12m
AMGNAmgen, Inc. 2.62%227.731.3%$540.12m
GILDGilead Sciences, Inc. 2.20%64.621.0%$516.91m
ILMNIllumina, Inc. -0.19%398.853.5%$484.87m
VRTXVertex Pharmaceuticals, Inc. 2.02%211.981.9%$458.30m
ALXNAlexion Pharmaceuticals, Inc. 1.11%150.102.0%$339.49m
BIIBBiogen, Inc. 2.71%270.711.7%$305.38m
CRSPCRISPR Therapeutics AG -0.73%114.650.6%$304.78m
BNGOBioNano Genomics, Inc. 3.62%7.150.0%$275.81m
EXASEXACT Sciences Corp. 0.51%121.6418.4%$251.13m
SGENSeagen Inc. 2.68%149.355.8%$225.25m
PACBPacific Biosciences of California, Inc. 1.70%29.277.2%$176.23m

Company Profile

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, they are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.